Skip to content
DataLookout
Menu

HER2-Positive Cancer clinical trials

Get alerts when HER2-Positive Cancer trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

22 trials changed in the last 30 days: 1 stopped, 10 with notable changes, 11 with minor changes only.

  1. Notable: MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) Recruitment opened Imagion Biosystems, Inc.Phase 1/2 NCT07885683
  2. Notable: IAM1363 in HER2 Cancers Primary completion pushed from Dec 2027 to Oct 2028 Iambic Therapeutics, IncPhase 1/2 NCT06253871
  3. Notable: DB-Guide · T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Start date pushed from Sep 18, 2026 to Nov 4, 2026 Daiichi SankyoPhase 3 NCT07683754
  4. Minor: EmpowHER 208 · Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy · HER2-positive Breast Cancer Trial sites expanded: 53 → 60 locations Jazz PharmaceuticalsPhase 2 NCT07102381
  5. Notable: VRN101099 · HER2-Positive Solid Tumors Primary completion pushed from May 1, 2026 to Mar 1, 2027 Voronoi, IncPhase 1 NCT06806982
  6. Minor: Pyrotinib, Trastuzumab Combined With Taxanes · Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC) Enrollment closed, study ongoing Hebei Medical University Fourth HospitalPhase 4 NCT06217185
  7. Stopped: Immune Response to Anti-HER2 Therapies · HER2-Positive Stage I-IV Breast Cancer Trial terminated Mayo ClinicNot specified NCT04517838
  8. Minor: NoCUT-BC · Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Primary and study completion pushed from Dec 31, 2027 to Jan 31, 2028 Ohio State University Comprehensive Cancer CenterPhase 1/2 NCT07217990
  9. Minor: Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Sichuan UniversityEarly Phase 1 NCT04684459
  10. Notable: At-Home Cancer Directed Therapy Versus in Clinic · Advanced Cancer Primary completion pushed from Jan 1, 2027 to Dec 1, 2027 Mayo ClinicPhase 2 NCT05969860
  11. Minor: BREnnA · RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine · Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Trial sites expanded: 206 → 219 locations Hoffmann-La RochePhase 2/3 NCT07413939
  12. Minor: Measuring the Effects of Talazoparib · Advanced Cancer and DNA Repair Variations Study completion pushed from Jul 27, 2027 to Oct 22, 2027 National Cancer Institute (NCI)Phase 2 NCT04550494
  13. Minor: Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine · Metastatic HER2 Positive Breast Cancer Study completion pushed from Sep 29, 2026 to Sep 7, 2027 City of Hope Medical CenterNot applicable NCT02226276
  14. Notable: SPECTACLE · Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer Recruitment opened Fudan UniversityPhase 2 NCT07581795
  15. Minor: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer Study completion pushed from Sep 25, 2026 to Aug 26, 2027 City of Hope Medical CenterPhase 2 NCT02827877
  16. Notable: DB-1303/BNT323 Versus T-DM1 in Breast Cancer Primary completion pushed from Feb 2026 to Dec 2027 DualityBio Inc.Phase 3 NCT06265428
  17. Notable: SuperHERO · Skipping Radiation Therapy · Breast Cancer Primary endpoint(s) modified Memorial Sloan Kettering Cancer CenterNot applicable NCT07895511
  18. Minor: Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer Start date pushed from Oct 2026 to Nov 2026 University of Wisconsin, MadisonPhase 2 NCT07706179
  19. Minor: NearWave Optical Molecular Monitoring Enrollment closed, study ongoing Indiana UniversityNot applicable NCT06744465
  20. Notable: ZOLA · Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Start date pushed from Oct 1, 2026 to Nov 30, 2026 Jazz PharmaceuticalsNot specified NCT07780968
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-10-30 NCT07907354 Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced… Yunnan Cancer Hospital new Phase 2
2026-10-21 NCT07885683 MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) Imagion Biosystems, Inc. new Phase 1/2
2026-10-02 NCT07856225 Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer Fundación Santa Fe de Bogota new

Active trials by phase

Early Phase 1
3
Phase 1
17
Phase 1/2
30
Phase 2
112
Phase 2/3
6
Phase 3
48
Phase 4
5
Not charted: 68 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when HER2-Positive Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free